Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Insight - RNAi: the long road from nucleotide to bedside

This article was originally published in Scrip

Executive Summary

The discovery of RNA interference (RNAi) fundamentally changed our understanding of biology, and created a powerful tool for biological research to harness this natural process. RNAi technology is an increasingly important platform for drug R&D with the potential to significantly expand the universe of druggable targets. Recently, a number of well-established pharmaceutical companies acquired or secured relationships with smaller companies to gain access to RNAi technology and drive RNAi therapeutics into the market. Like monoclonal antibodies before them, RNAi therapeutics represent a novel treatment modality that promise to usher in a new era of medicine. However, as with monoclonal antibodies, the process of developing a Nobel Prize-winning discovery through to widespread therapeutic use is likely to take time.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts